临床和临床前发表文章

YIV-818-A enhanced apalutamide, darolutamide and enzalutamide action for prostate cancer treatment by down-regulating androgen receptor protein, inhibiting glucocorticoid receptor function and epigenetic regulation

American Association for Cancer Research, 2023年4月

YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity

Frontiers in Pharmacology, 2023年1月

Preclinical Immunotherapy Research Featured in Poster Presentation at AACR 2022 Annual Meeting Highlights YIV-906’s Immunomodulatory Mechanisms in Combination with Immune Checkpoint or CAR T Therapy
American Association for Cancer Research, 2022年4月
AACR Abstract
AACR Poster

A Phase II Clinical Trial on the Combination Therapy of YIV-906 (PHY906) Plus Capecitabine in Hepatocellular Carcinoma
The Oncologist, 2021年3月

Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China
Frontiers in Pharmacology, 2021年2月

A phase II randomized placebo-controlled study of YIV-906 and sorafenib in Hepatitis B positive (HBV+) patients with advanced hepatocellular carcinoma (HCC), Journal of Clinical Oncology
ASCO, 2020年2月

The Evolution of Future Medicine – WE Medicine – To Meet Unmet Medical Needs
Novel Approaches in Cancer Study, 2019年11月

YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy (Anti-PD1) against liver cancer by changing the tumor micro-environment associated with M1 macrophages infiltration
American Association for Cancer Research, 2019年7月

Mechanism Based Quality Control (Mech QC) of Herbal Products- A Case Study YIV-906 (PHY906)
Frontiers in Pharmacology, 2018年11月

YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy: Anti-PD-1 against liver cancer
American Association for Cancer Research, 2018年7月

STAR Discovery Platform – Majority of Chinese Medicine Herb Category QingReYao Have Multiple Mechanisms of Anti-Inflammatory Activity
Scientific Reports, 2018年5月

Wedding Rigorous Scientific Methodology and Ancient Herbal Wisdom to Benefit Cancer Patients: The Development of YIV-906 (PHY906)
CancerNetwork – Oncology Journal, 2018年2月

Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer
Annals of Oncology, 2018年6月

Pilot trial of YIV-906 (KD018) with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
ASCO, 2017年6月

YIV-906 (PHY906, KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
Scientific Reports, 2015年3月

The Art and Science of Traditional Medicine – Lessons from the Development of the Chinese Formula YIV-906 (PHY906)
Science, 2015年1月

The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine YIV-906 (PHY906, KD018)
BMC Complementary and Alternative Medicine, 2014年7月

First-in-human Phase II trial of the Botanical Formulation YIV-906 (PHY906) with Capecitabine as Second-line Therapy in Patients with Advanced Pancreatic Cancer
Cancer Chemotherapy Pharmacology, 2014年2月

Preclinical Studies of the Chinese Herbal Medicine formulation YIV-906 (PHY906) as a Potential Adjunct to Radiation Therapy
International Journal of Radiation Biology, 2013年1月

Evidence-based Anticancer Materia Medica for Pancreatic Cancer
from Chapter 11 – Evidence-based Anti-cancer Complementary and Alternative Medicine: Herbal Medicine for Various Cancers, Springer, 2012

Interaction of a traditional Chinese Medicine YIV-906 (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment
BMC Medical Genomics, 2011年5月

A Phase I Study of the Chinese Herbal Medicine YIV-906 (PHY906) as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer
Clinical Colorectal Cancer, 2010年8月

The Four Herb Chinese Medicine YIV-906 (PHY906) Reduces Chemotherapy Induced Gastrointestinal Toxicity
Science Translational Medicine, 2010年8月

Any Second-Line Therapy for Advanced Pancreatic Cancer? Highlights from the “2010 ASCO Gastrointestinal Cancers Symposium”
Journal of the Pancreas, 2010年3月

Phase II study of YIV-906 (PHY906) plus capecitabine in patients with gemcitabine-refractory pancreatic cancer and measurement of cytokines
ASCO, 2010年5月

Phase I study of the botanical formulation YIV-906 (PHY906) with capecitabine in advanced pancreatic and other gastrointestinal malignancies
Phytomedicine, 2010年3月

Phase I/II Study of YIV-906 (PHY906) plus Capecitabine in Advanced Hepatocellular Carcinoma
Anticancer Research, 2009年10月

Exploration of the mechanisms of YIV-906 (PHY906) in reducing the intestinal toxicity caused by irinotecan
American Association for Cancer Research, 2009年4月

Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the “44th ASCO Annual Meeting”
Journal of the Pancreas, 2008年7月

A phase I/II study of YIV-906 (PHY906) plus capecitabine in patients with advanced pancreatic cancer
ASCO, 2008年5月

YIV-906 (PHY906) in hepatocellular carcinoma
American Association for Cancer Research, 2007年5月

YIV-906 (PHY906) as a broad-spectrum enhancer in cancer therapy: Clinical and preclinical results in hepatocellular carcinoma
American Association for Cancer Research, 2006年4月

Developing YIV-906 (PHY906) as a broad- spectrum modulator of chemotherapeutic agents in cancer therapy
American Association for Cancer Research, 2004年4月

Definition of Chinese herbal formulation YIV-906 (PHY906)
National Cancer Institute – NCI Drug Dictionary